Welcome to our dedicated page for Align Technology news (Ticker: ALGN), a resource for investors and traders seeking the latest updates and insights on Align Technology stock.
Align Technology reports developments in digital orthodontics and restorative dentistry through its Invisalign System of clear aligners, iTero intraoral scanners, exocad CAD/CAM software and the Align Digital Platform. Company news commonly covers product and workflow updates for clear-aligner treatment planning, intraoral scanning, 3D visualization and digitally connected dental practices.
Recurring updates also include quarterly and annual operating results, clear-aligner shipment and channel trends, regional demand, foreign-exchange effects, stock repurchase activity, financial-conference participation and governance or shareholder-voting matters. Other announcements describe clinical education, professional collaborations and access-to-care initiatives involving orthodontists, general practitioner dentists and dental research organizations.
Align Technology has launched the new iTero Workflow 2.0 software, enhancing practice efficiency with features like faster scanning, improved visualization, and advanced patient communication tools. The software, set to be available in Q3 2021, streamlines Invisalign case submissions by allowing intraoral color scan images instead of traditional photos. The iTero Element 5D Plus imaging system will support these upgrades, aiming to boost clinical diagnosis and patient engagement for better treatment acceptance.
Align Technology (Nasdaq: ALGN) has awarded $250,000 in research grants as part of its eleventh Annual Research Award Program, aimed at advancing dental and orthodontic treatments. Since 2010, the company has funded over $2.0 million in research, receiving numerous applications from global universities. The awarded studies cover diverse topics in orthodontics and dentistry, highlighting Align's commitment to innovation and improving oral health outcomes.
Align Technology (Nasdaq: ALGN) announced its participation in several upcoming financial conferences, where key executives will present details about the company and its offerings. The presentations will be webcast live from Align's Investor Relations website, with archived replays available for three months. Notable events include the William Blair Growth Stock Conference on June 1, Stifel Jaws & Paws Conference on June 2, Jefferies Healthcare Conference on June 3, Goldman Sachs Healthcare Conference on June 9, and the Nasdaq Investor Conference on June 16.
Align Technology, Inc. (Nasdaq: ALGN) has announced a new accelerated stock repurchase agreement with Goldman Sachs to buy back $100 million of its common stock. This repurchase is part of Align's $1.0 billion stock buyback program initiated on May 13, 2021. Under the ASR, Align will initially acquire about 143,000 shares, with the final total dependent on the stock's volume-weighted average price. The transaction is anticipated to conclude by August 2021 and will utilize Align's cash reserves, which stood at $1.1 billion as of March 31, 2021.
Align Technology (Nasdaq: ALGN) announced the launch of new consumer campaigns aimed at increasing demand for Invisalign treatment among teens and young adults. The multi-touch campaign builds on previous efforts, leveraging data analytics and engaging digital content through influencers. Align invests over $250 million annually in brand awareness to connect with potential patients. Currently, over 10 million consumers have utilized Invisalign for orthodontic treatment. The campaign will target various markets globally, starting in the US before expanding to regions including Australia, the UK, and Brazil.
Align Technology (ALGN) has authorized a new stock repurchase program, allowing the company to buy back up to $1.0 billion of its common stock over the next three years. This decision reflects the strength of Align's balance sheet and its commitment to returning capital to shareholders. The new program follows a $600 million repurchase authorization from May 2018, which included a $100 million accelerated stock repurchase transaction. Align currently has approximately 79.1 million shares outstanding and $1.1 billion in cash and cash equivalents.
Align Technology supports the updated policy statement from the General Dental Council (GDC), highlighting the necessity of a physical examination before orthodontic treatments. This ensures thorough assessment of patients' oral health and mandates that patients are informed about the dental professionals responsible for their care. Julie Coletti, the company’s legal officer, commended the GDC for its role in upholding dental standards in the UK, emphasizing that proper orthodontic treatment must be delivered by qualified professionals following in-person evaluations.
Align Technology (Nasdaq: ALGN) will participate in several upcoming financial conferences. The presentations will be webcast live via their Investor Relations website, with archived replays available for three months. Key dates include:
- BofA Securities Virtual Healthcare Conference on May 12, 2021, from 11:45 AM to 12:15 PM ET.
- Berenberg US Conference 2021 on May 20, 2021, with no formal presentation.
- UBS Global Healthcare Conference on May 26, 2021, from 9:00 AM to 9:45 AM ET.
Align designs the Invisalign system and has treated over 10.2 million patients.
Summary not available.
Align Technology has initiated an accelerated stock repurchase (ASR) agreement with Goldman Sachs to buy back $100 million of its common stock, part of a larger $600 million repurchase program announced in 2018. The ASR will lead to an initial delivery of approximately 134,300 shares, with the final amount determined by the stock's average price during the buyback period. Completion of the ASR is expected by August 2021. Align holds around $1.1 billion in cash and equivalents, which will fund this transaction.